CEO of Quotient Therapeutics and Flagship Origination Partner Jake Rubens explains how the company’s Somatic Genomics platform is finding new drug targets across a wide range of diseases and why Quotient is capturing the attention of partners like Pfizer. More from Flagship @ JPM2025 here.
Related Companies
- Quotient Therapeutics Founded: 2022
